Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
OBJECTIVE
To analyse the safety and efficacy of the off-label use of rituximab in patients with severe, refractory systemic autoimmune diseases.


METHODS
In 2006, the Study Group on Autoimmune Diseases of the Spanish Society of Internal Medicine created the BIOGEAS project, a multicenter study devoted to collecting data on the use of biological agents in adult patients with systemic autoimmune diseases refractory to standard therapies (failure of at least two immunosuppressive agents).


RESULTS
One hundred and ninety-six patients with systemic autoimmune diseases treated with rituximab have been included in the Registry (158 women and 38 men, mean age 43 years). Systemic autoimmune diseases included systemic lupus erythematosus (107 cases), inflammatory myopathies (20 cases), ANCA-related vasculitides (19 cases), Sjögren's syndrome (15 cases) and other diseases (35 cases). A therapeutic response was evaluable in 194 cases: 99 (51%) achieved a complete response, 51 (26%) a partial response and 44 (23%) were classified as non-responders. After a mean follow-up of 27.56+/-1.32 months, 44 (29%) out of the 150 responders patients relapsed. There were 40 adverse events reported in 33 (16%) of the 196 patients. The most frequent adverse events were infections, with 24 episodes being described in 19 patients. Thirteen (7%) patients died, mainly due to disease progression (7 cases) and infection (3 cases).


CONCLUSIONS
Although not yet licensed for this use, rituximab is currently used to treat severe, refractory systemic autoimmune diseases, with the most favourable results being observed in Sjögren's syndrome, inflammatory myopathies, systemic lupus erythematosus and cryoglobulinemia.
Ramos-Casals
M
M
Laboratorio de Enfermedades Autoinmunes Josep Font, IDIBAPS, Hospital Clínic, Barcelona. Spain. mramos@clinic.ub.es
García-Hernández
F J
FJ
de Ramón
E
E
Callejas
J L
JL
Martínez-Berriotxoa
A
A
Pallarés
L
L
Caminal-Montero
L
L
Selva-O'Callaghan
A
A
Oristrell
J
J
Hidalgo
C
C
Pérez-Alvarez
R
R
Micó
M L
ML
Medrano
F
F
Gómez de la Torre
R
R
Díaz-Lagares
C
C
Camps
M
M
Ortego
N
N
Sánchez-Román
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy / Q000208:ethnology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000208:ethnology; D003449:Cryoglobulinemia / Q000188:drug therapy / Q000208:ethnology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000208:ethnology; D008297:Male; D008875:Middle Aged; D009220:Myositis / Q000188:drug therapy / Q000208:ethnology; D056687:Off-Label Use; D012189:Retrospective Studies; D000069283:Rituximab; D012720:Severity of Illness Index; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000208:ethnology; D013030:Spain; D016896:Treatment Outcome; D055815:Young Adult
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab